Guggenheim raises Damora Therapeutics price target on MF sales outlook

Guggenheim upgraded its price target on Damora Therapeutics (NASDAQ:DMRA) stock to $60 from $40 on Thursday, while keeping the stock on a Buy rating. The firm also raised its sales forecast for the mCALR antibody class in myelofibrosis to around $3 billion from $1 billion. Guggenheim now anticipates the combined multiple myeloma and erythroleukemia markets can produce over $5 billion in class sales, supporting various players.

This new estimate stems from two changes to Guggenheim's multiple myeloma model. The first is that the firm now expects earlier drug intervention compared to Jakafi, which is typically initiated after a watch-and-wait strategy. The second is a forecasted increase in treated prevalence due to longer therapy duration and better survival outcomes compared to Jakafi’s usual one-to-three-year use.

Damora shares have fallen about 40% from last quarter’s peak, while the XBI index has only dropped about 8%. This makes Damora shares down approximately 40% from last quarter’s high, compared to an 8% decline in the XBI index, on concerns about emerging competitors such as Incyte and Calytrix. The stock has also declined 10% over the past week alone, trading at $20.27, significantly below its 52-week high of $38.33.

Despite this recent downturn, the stock has still managed a remarkable 356% return over the past year. Guggenheim sees the current level as a good entry point, supported by technical indicators like an RSI suggesting the stock is in oversold territory. InvestingPro provides 10 additional exclusive tips for DMRA, along with detailed financial metrics to help investors make informed decisions.

Damora Therapeutics recently completed a redomestication from Delaware to the Cayman Islands, automatically converting each outstanding common and preferred stock share into the corresponding shares of the redomesticated company. This structural change has been reported separately. Analyst coverage includes Jefferies with a Buy rating and a $50.00 price target, and H.C.

Wainwright reiterating its Buy rating with a $45.00 price target. Both analysts highlight the potential of Damora's ongoing developments in their respective analyses.